Traversa Sergio's Form 4 filing
Relmada Therapeutics, Inc. (RLMD) · filed Aug 28, 2025
- Accession no.
- 0001213900-25-081837
- Filed
- Aug 28, 2025
- Trade date
- Aug 26-28, 2025
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 3 non-derivative transactions. Open-market purchases total $178.1K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Traversa SergioCIK 0001565832 | Director, Officer (Chief Executive Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 26, 2025 | Common Stock | PPurchaseAcquired | +80,545 | $0.62 | +$49,937.9 | 814,569 | Direct | |
| Aug 27, 2025 | Common Stock | PPurchaseAcquired | +129,455 | $0.67 | +$86,734.85 | 944,024 | Direct | |
| Aug 28, 2025 | Common Stock | PPurchaseAcquired | +55,976 | $0.74 | +$41,422.24 | 1,000,000 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.